Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors

Area of Science:

• Drug development and regulatory science
• Bioethics
• Clinical pharmacology

Background:

• Expanded access allows investigational drugs for serious conditions without satisfactory treatments.
• Expanded access programs (EAPs) are formal plans for providing pre-approval drug access.
• Sponsors hold the ultimate decision-making authority for authorizing EAPs.

Purpose of the Study:

• To propose a framework for sponsor decisions on Expanded Access Programs (EAPs).
• To advocate for integrating ethical and practical considerations into EAP authorization.
• To ensure EAP implementation aligns with ethical principles like fairness and harm minimization.

Main Methods:

• Literature review of regulatory guidelines for expanded access.
• Ethical analysis of sponsor decision-making in EAPs.
• Framework development based on regulatory, ethical, and practical criteria.

Main Results:

• Current EAP authorization relies heavily on regulatory compliance.
• Ethical and practical factors are crucial but often secondary in sponsor decisions.
• A comprehensive approach is needed to balance patient access with responsible drug development.

Conclusions:

• Sponsor decisions for EAPs must integrate regulatory, ethical, and practical considerations.
• Implementing EAPs requires careful planning to uphold fairness and minimize harm.
• A balanced approach ensures EAPs benefit patients, drug development, and future patient populations.